Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss

Ear and Hearing

Volumn 29, Issue 6, 2008, Pages 875-893

  Reavis, Kelly M ^a   Phillips, David S ^a   Fausti, Stephen A ^a,b   Gordon, Jane S ^a   Helt, Wendy J ^a   Wilmington, Debra ^a   Bratt, Gene W ^c,d   Konrad Martin, Dawn ^a,b  

^a NATIONAL CENTER FOR REHABILITATIVE AUDITORY RESEARCH   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; GENTAMICIN; PLATINUM DERIVATIVE; VANCOMYCIN; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT;

ARTICLE; AUDITORY THRESHOLD; DISTORTION PRODUCT OTOACOUSTIC EMISSION; EAR; HEARING LOSS; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OTOTOXICITY; PREDICTION; PROSPECTIVE STUDY; PURE TONE AUDIOMETRY; UNIVARIATE ANALYSIS; AGED; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; DRUG MONITORING; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SPONTANEOUS OTOACOUSTIC EMISSION;

AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTINEOPLASTIC AGENTS; AUDIOMETRY, PURE-TONE; AUDITORY THRESHOLD; CARBOPLATIN; CISPLATIN; DRUG MONITORING; FEMALE; HEARING LOSS; HUMANS; MALE; MIDDLE AGED; OTOACOUSTIC EMISSIONS, SPONTANEOUS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 60849108668     PISSN: 01960202     EISSN: None     Source Type: Journal    
DOI: 10.1097/AUD.0b013e318181ad99     Document Type: Article

References (76)

1. American National Standards Institute. (1989). American national standard specification for audiometers. ANSI S3.6-1989. New York: ANSI.
2. American Speech-Language-Hearing Association. (1994). Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA, 36, 11-19.
3. Arnold, D. J., Lonsbury-Martin, B. L., & Martin, G. K. (1999). High-frequency hearing influences lower-frequency distortion-product otoacoustic emissions. Arch Otolaryngol Head Neck Surg, 125, 215-222. (Pubitemid 29085271)
4. Avan, P., Bonfils, P., Loth, D., et al. (1993). Exploration of cochlear function by otoacoustic emissions: relationship to pure-tone audiometry. Prog Brain Res, 97, 67-75. (Pubitemid 23313437)
5. Bates, D. E., Beaumont, S. J., & Baylis, B. W. (2002). Ototoxicity induced by gentamicin and furosemide. Ann Pharmacother, 36, 446-451.
6. Beattie, R. C., Kenworthy, O. T., & Luna, C. A. (2003). Immediate and short-term reliability of distortion-product otoacoustic emissions. Int J Audiol, 42, 348-354. (Pubitemid 37345312)
7. Blakley, B. W., Gupta, A. K., Myers, S. F., et al. (1994). Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg, 120, 541-546.
8. Brummett, R. E. (1980). Drug-induced ototoxicity. Drugs, 19, 412-428.
9. Brummett, R. E. & Fox, K. E. (1989). Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother, 33, 797-800.
10. Campbell, K. C. & Durrant, J. (1993). Audiologic monitoring for ototoxicity. Otolaryngol Clin North Am, 26, 903-914.
11. Carhart, R. & Jerger, J. (1959). Preferred method for clinical determination of pure-tone thresholds. J Speech Hear Disord, 24, 330-345.
12. Cavaletti, G., Bogliun, G., Zincone, A., et al. (1998). Neuro and ototoxicity of high dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Res, 18, 3797-3802. (Pubitemid 28564269)
13. de Jongh, F. E., van Veen, R. N., Veltman, S. J., et al. (2003). Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 4000 patients. Br J Cancer, 88, 1199-1206.
14. DeLauretis, A., DeCapua, B., Barbieri, M. T., et al. (1999). ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin. Scand Audiol, 28, 139-143.
15. Dobie, R. A. (2005). Audiometric threshold shift definitions: simulations and suggestions. Ear Hear, 26, 62-77.
16. Dreisbach, L. E., Long, K. M., & Lees, S. E. (2006). Repeatability of high-frequency distortion-product otoacoustic emissions in normal-hearing adults. Ear Hear, 27, 466-479.
17. Dreschler, W. A., van der Hulst, R. J., Tange, R. A., et al. (1989). Role of high-frequency audiometry in the early detection of ototoxicity. II. Clinical aspects. Audiology, 28, 211-220.
18. Ellison, J. C. & Keefe, D. H. (2005). Audiometric predictions using stimulus-frequency otoacoustic emissions and middle ear measurements. Ear Hear, 26, 487-503.
19. Estrem, S. A., Babin, R. W., Ryu, J. H., et al. (1981). Cis-diamminedichloroplatinum (II) ototoxicity in the guinea pig. Otolaryngol Head Neck Surg, 89, 638-645.
20. Fausti, S. A., Frey, R. H., Erickson, D. A., et al. (1979). A system for evaluating auditory function from 8000-20 000 Hz. J Acoust Soc Am, 66, 1713-1718.
21. Fausti, S. A., Frey, R. H., Henry, J. A., et al. (1990). Reliability and validity of high-frequency (8-20 kHz) thresholds obtained on a computer-based audiometer as compared to a documented laboratory system. J Am Acad Audiol, 1, 162-170.
22. Fausti, S. A., Helt, W. J., Phillips, D. S., et al. (2003). Early detection of ototoxicity using 1/6th-octave steps. J Am Acad Audiol, 14, 444-450.
23. Fausti, S. A., Henry, J. A., Helt, W. J., et al. (1999). An individualized, sensitive frequency range for early detection of ototoxicity. Ear Hear, 20, 497-505.
24. Fausti, S. A., Henry, J. A., Schaffer, H. I., et al. (1993). High-frequency monitoring for early detection of cisplatin ototoxicity. Arch Otolaryngol Head Neck Surg, 119, 661-665.
25. Fausti, S. A., Henry, J. A., Schaffer, H. I., et al. (1992). High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis, 165, 1026-1032.
26. Fausti, S. A., Larson, V. D., Noffsinger, D., et al. (1994). High-frequency audiometric monitoring strategies for early detection of ototoxicity. Ear Hear, 15, 232-239. (Pubitemid 24173826)
27. Fausti, S. A., Rappaport, B. Z., Schechter, M. A., et al. (1984). Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation: selected case studies. Am J Otolaryngol, 5, 177-182.
28. Fischel-Ghodsian, N., Prezant, T. R., Bu, X., et al. (1993). Mitochondrial ribosomal RNA gene mutation in a patient with sporadic aminoglycoside ototoxicity. Am J Otolaryngol, 14, 399-403. (Pubitemid 23337068)
29. Forge, A. & Schacht, J. (2000). Aminoglycoside antibiotics. Audiol Neurootol, 5, 3-22.
30. Franklin, D. J., McCoy, M. J., Martin, G. K., et al. (1992). Test/retest reliability of distortion-product and transiently evoked otoacoustic emissions. Ear Hear, 13, 417-429. (Pubitemid 23019460)
31. Gorga, M. P., Neely, S. T., Bergman, B., et al. (1993). Otoacoustic emissions from normal-hearing and hearing-impaired subjects distortion product responses. J Acoust Soc Am, 93, 2050-2060. (Pubitemid 23110792)
32. Gorga, M. P., Neely, S. T., Ohlrich, B., et al. (1997). From laboratory to clinic: a large scale study of distortion product otoacoustic emissions in ears with normal hearing and ears with hearing loss. Ear Hear, 18, 440-455. (Pubitemid 28012101)
33. Gorga, M. P., Stover, L., Neelys, S. T., et al. (1996). The use of cumulative distributions to determine critical values and levels of confidence for clinical distortion product otoacoustic emission measurements. J Acoust Soc Am, 100, 968-977. (Pubitemid 26265190)
34. Hinojosa, R., Nelson, E. G., Lerner, S. A., et al. (2001). Aminoglycoside ototoxicity: a human temporal bone study. Laryngoscope, 111, 1797-1805. (Pubitemid 32946457)
35. Hinojosa, R., Riggs, L. C., Strauss, M., et al. (1995). Temporal bone histopathology of cisplatin ototoxicity. Am J Otol, 16, 731-740.
36. Hodges, A. V. & Lonsbury-Martin, B. L. (1999). Hearing management. In P.A. Sullivan, & A.MGuilford (Eds.), Best practices in oncology management: focus on swallowing and communication disorders (pp. 269-290). San Diego, CA: Singular Publishing Group.
37. Hofstetter, P., Ding, D., Powers, N., et al. (1997). Quantitative relationship of carboplatin dose to magnitude of inner and outer hair cell loss and the reduction in distortion product otoacoustic emission amplitude in chinchillas. Hear Res, 112, 199-215. (Pubitemid 27435996)
38. Hoistad, D. L., Ondrey, F. G., Mutlu, C., et al. (1998). Histopathology of human temporal bone after cis-platinum, radiation, or both. Otolaryngol Head Neck Surg, 118, 825-832. (Pubitemid 28307471)
39. Katbamna, B., Homnick, D. N., & Marks, J. H. (1999). Effects of chronic tobramycin treatment on distortion product otoacoustic emissions. Ear Hear, 20, 393-402. (Pubitemid 29483445)
40. Kennedy, I. C., Fitzharris, B. M., Colls, B. M., et al. (1990). Carboplatin is ototoxic. Cancer Chemother Pharmacol, 26, 232-234.
41. Kim, D. O. (1980). Cochlear mechanics: implications of electrophysiological and acoustical observations. Hear Res, 2, 297-317.
42. Komune, S., Asakuma, S., & Snow, J. B. Jr. (1981). Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum. Otolaryngol Head Neck Surg, 89, 275-282.
43. Konishi, T., Gupta, B. N., & Prazma, J. (1983). Ototoxicity of cis-dichlorodiammine platinum (II) in guinea pigs. Am J Otolaryngol, 4, 18-26.
44. Kopelman, J., Budnick, A. S., Sessions, R. B., et al. (1988). Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope, 98(8 pt 1), 858-864. (Pubitemid 18201354)
45. Lesar, R. S. (1993). Drug-induced ear and eye toxicity. In J. T. Di Piro, R. L. Talbert, P. E. Hayes, et al. (Eds.), Pharmacotherapy: a pathophysiologic approach (2nd ed., pp. 1349-1362). Norwalk, CT: Appleton & Lange.
46. Littman, T. A., Magruder, A., & Strother, D. R. (1998). Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions: pediatric case study. J Am Acad Audiol, 9, 257-262.
47. Martin, G. K., Lonsbury-Martin, B. L., Probst, R., et al. (1987). Acoustic distortion products in rabbits II. Sites of origin revealed by suppression contours and pure-tone exposures. Hear Res, 28, 191-208. (Pubitemid 17102433)
48. Meech, R. P., Campbell, K. C., Hughes, L. P., et al. (1998). A semiquantitative analysis of the effects of cisplatin on the rat stria vascularis. Hear Res, 124, 44-59.
49. Moore, R. D., Smith, C. R., & Lietman, P. S. (1984). Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis, 149, 23-30. (Pubitemid 14179885)
50. Mulheran, M. & Degg, C. (1997). Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects. Br J Audiol, 31, 5-9. (Pubitemid 27095625)
51. Neeley, S. T. & Gorga, M. P. (1998). Comparison between intensity and pressure as measures of sound level in the ear canal. J Acoust Soc Am, 104, 2925-2934.
52. Nakai, Y., Konishi, K., Chang, K. C., et al. (1982). Ototoxicity of the anticancer drug cisplatin. An experimental study. Acta Otolaryngol, 93, 227-232. (Pubitemid 12173676)
53. Ozturan, O. & Lam, S. (1996). The effect of hemodialysis on hearing using pure-tone audiometry and distortion-product otoacoustic emissions. ORL J Otorhinolaryngol Relat Spec, 60, 306-313. (Pubitemid 28464319)
54. Parsons, S. K., Neault, M. W., Lehmann, L. E., et al. (1998). Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant, 22, 669-674.
55. Peloquin, C. A., Berning, S. E., Nitta, A. T., et al. (2004). Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis, 38, 1538-1544.
56. Ress, B. D., Sridhar, K. S., Balkany, T. J., et al. (1999). Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Otolaryngol Head Neck Surg, 121, 693-701.
57. Roede, J., Harris, F. P., Probst, R., et al. (1993). Repeatability of distortion product otoacoustic emissions in normally hearing humans. Audiology, 32, 273-281. (Pubitemid 23256044)
58. Schaefer, S. D., Post, J. D., Close, L. G., et al. (1985). Ototoxicity of low- and moderate-dose cisplatin. Cancer, 56, 1934-1939.
59. Schweitzer, V. G. (1993). Cisplatin-induced ototoxicity: effect of pigmentation and inhibitory agents. Laryngoscope, 103(Suppl 59), 1-52. (Pubitemid 23139805)
60. Schweitzer, V. G., Hawkins, J. E., Lilly, D. J., et al. (1984). Ototoxic and nephrotoxic effects of combined treatment with cis-diamminedichloroplatinum and kanamycin in the guinea pig. Otolaryngol Head Neck Surg, 92, 38-49.
61. Seligmann, H., Podoshin, L., Ben-David, J., et al. (1996). Drug-induced tinnitus and other hearing disorders. Drug Safety, 13, 198-212. (Pubitemid 26086056)
62. Shera, C. A. & Guinan, J. J. (1999). Evoked otoacoustic emissions arise by two fundamentally different mechanisms: a taxonomy for mammalian OAEs. J Acoust Soc Am, 105, 782-798. (Pubitemid 129504229)
63. Siegel, J. H. (1994). Ear-canal standing waves and high-frequency sound calibration using otoacoustic emission probes. J Acoust Soc Am, 95, 2589-2597.
64. Siegel, J. H. (2002). Calibration otoacoustic emission probes. In M. S. Robinette & T. J. Glattke (Eds.), Otoacoustic emissions: clinical applications (pp. 416-438). New York: Thieme.
65. Siegel, J. H. & Kim, D. O. (1982). Cochlear biomechanics: vulnerability to acoustic trauma and other alterations as seen in neural responses and ear-canal sound pressure. In D. Hamernik, D. Henderson, & R. Salvi (Eds.), New perspectives on noise-induced hearing loss (pp. 137-151). New York: Raven Press.
66. Stavroulaki, P., Apostolopoulos, N., Segas, J., et al. (2001). Evoked otoacoustic emissions - an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol, 59, 47-57. (Pubitemid 32453343)
67. Stavroulaki, P., Vossinakis, I. C., Dinopoulou, D., et al. (2002). Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis. Arch Otolaryngol Head Neck Surg, 128, 150-155. (Pubitemid 34132170)
68. Tange, R. A. (1984). Differences in the cochlear degeneration pattern in the guinea pig as a result of gentamicin and cis-platinum intoxication. Clin Otolaryngol Allied Sci, 9, 323-327.
69. Tange, R. A., Dreschler, W. A., & van der Hulst, R. J. (1985). The importance of high-tone audiometry in monitoring for ototoxicity. Arch Otorhinolaryngol, 242, 77-81.
70. Trautwein, P., Hofstetter, P., Wang, J., et al. (1996). Selective inner hair cell loss does not alter distortion product otoacoustic emissions. Hear Res, 96, 71-82. (Pubitemid 26251812)
71. Tsukasaki, N., Whitworth, C. A., & Rybak, L. P. (2000). Acute changes in cochlear potentials due to cisplatin. Hear Res, 149, 189-198. (Pubitemid 30734438)
72. van der Hulst, R. J., Dreschler, W. A., & Urbanus, N. A. (1988). High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol, 97(2 pt 1), 133-137.
73. Vaughan, N. E., Fausti, S. A., Chelius, S., et al. (2002). An efficient test protocol for identification of a limited, sensitive frequency test range for early detection of ototoxicity. J Rehab Res Develop, 39, 567-574. (Pubitemid 35388076)
74. Waters, G. S., Ahmad, M., Katsarkas, A., et al. (1991). Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear, 12, 91-102.
75. Whitehead, M. L., Lonsbury-Martin, B. L., Martin, G. K., et al. (1996). Otoacoustic emissions: Animal models and clinical observations. In T.R. Van De Water, A.N. Popper, & R.R. Fay (Eds.), Clinical aspects of hearing (pp. 199-257). New York, NY: Springer-Verlag.
76. Whitehead, M. L., Stagner, B. B., Lonsbury-Martin, B. L., et al. (1995). Effects of ear-canal standing waves on measurements of distortion-product otoacoustic emissions. J Acoust Soc Am, 98, 3200-3214.